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ABSTRACT
Objectives: To explore whether pharmacokinetic (PK)
studies in paediatric patients are becoming less
invasive. This will be evaluated by analysing the
number of samples and volume of blood collected for
each study within four different decades.
Methods: A systematic literature review was
performed to identify PK papers describing number of
samples and volume of blood collected in studies of
children aged 0–18 years. The following databases
were searched: MEDLINE (1946 to December 2015),
EMBASE (1974 to December 2015), International
Pharmaceutical Abstracts (1970 to December 2015),
CINAHL and Cochrane Library.
Results: A total of 549 studies were identified
between 1974 and 2015. There were 52 studies
between 1976 and 1985, 105 between 1986 and 1995,
201 between 1996 and 2005 and 191 between 2006
and 2015. The number of blood samples collected per
participant increased between the first two decades
(p=0.013), but there was a decrease in the number of
samples in the subsequent two decades (p=0.044 and
p<0.001, respectively). Comparing the first and last
decades, there has been no change in the number of
blood samples collected. There were no significant
differences in volume collected per sample or total
volume per child in any of the age groups. There was
however a significant difference in the frequency of
blood sampling between population PK studies
(median 5 (IQR 3–7)) and non-population PK studies
(median 8 (IQR 6–10); p=<0.001).
Conclusions: The number of blood samples collected
for PK studies in children rose in 1985–1995 and
subsequently declined. There was no overall change in
the volume of blood collected over the 4 decades. The
usage of population PK methods reduces the frequency
of blood sampling in children.
INTRODUCTION
Clinical pharmacokinetics is the study of the
relationships between drug dosage regimens
and concentration–time proﬁles.1 These
studies are essential in paediatric patients as
they help determine the correct dose and
regimen. While it is important to perform
invasive clinical research in children, this
should be done in an ethical manner.
Venepuncture is the most common invasive
procedure within pharmacokinetic (PK)
studies. This procedure has been shown to
cause psychological and physical pain in chil-
dren.2 The expectation of pain is a common
psychological problem and may contribute to
difﬁculty in blood sampling in children.3
Physiological implications of blood sampling,
especially in preterm neonates, are that
excessive blood sampling may compromise
circulation and lead to a need for transfu-
sion. Venepuncture may also cause physical
risks such as bruising to the child4 and fre-
quent sampling can be associated with infec-
tion.5 The choice of sampling site depends
on the age, weight and the volume of blood
required. Heel prick is usually done for
infants <6 months old or between 3 and
10 kg. Finger prick can be used for children
over 6 months and more than 10 kg.6
Adult PK studies cannot be used to deter-
mine paediatric characteristic; therefore, PK
studies in children are essential. Children
have a lower total blood volume (TBV) and
tend not to tolerate pain. Invasiveness can be
minimised by scavenging blood collected for
diagnostic purpose and taking samples at the
same time as clinical samples. Micro-samples
have reduced the volumes of blood required
for analysis, and several studies have demon-
strated their usefulness in estimating PK
parameters in neonates and children.7–9
Similarly, the technique of population-based
parametric PK estimation has been used to
facilitate fewer samples for each individual
child.
Strengths and limitations of this study
▪ A systematic literature review of published
pharmacokinetic (PK) studies in children.
▪ Comparison of number of blood samples,
individual and total blood volume collected.
▪ Some studies did not report the results for
different paediatric age groups.
▪ Some studies were limited by the lack of data on
weight and volume.
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Different guidelines on the safe limit for blood sam-
pling have been proposed. The European Medicines
Agency (EMA) recommends that not >3% of TBV of
neonates should be withdrawn during a period of
4 weeks and at a single time, drawn blood should not
exceed 1% of TBV.10 The US Department of Health and
Human Services, on the other hand, recommends that
not >3.8% (3 mL/kg) of the TBV should be withdrawn
at once.11 The number of samples required for PK
studies varies with the research question. There is no
standard guideline on the frequency of blood sampling
in children.
A review of invasiveness of PK studies in children has not
been conducted. Therefore, our aim was to explore
whether PK studies in paediatric patients are becoming
less invasive. We therefore decided to perform a systematic
review of frequency and volume of blood sampling in PK
studies in paediatric patients and compare four decades.
METHOD
A systematic literature search was performed to identify
all papers describing the number of samples and
volume of blood collected in paediatric patients of all
ages up to 18 years. The following databases were used:
MEDLINE (1946 to December 2015), EMBASE (1974 to
December 2015), International Pharmaceutical Abstracts
(1970 to December 2015), CINAHL and Cochrane
Library (ﬁgure 1). The databases were searched separ-
ately and combined together to remove duplications.
The search strategy included all languages and involved
the keywords ‘preterm neonate*’ OR ‘term neonate*’ OR
‘neonate*’ OR ‘new-born*’ OR ‘child*’ OR children OR
‘p*ediatric*’ OR ‘infant*’ OR ‘adolescent*’12 AND ‘phar-
macokinetic*’ OR blood OR plasma OR specimen OR
serum OR blood sampling OR ‘blood sample*’ (see online
supplementary table S1). After screening the abstract for
duplicates and irrelevant studies, a further screening of full
articles was performed. A manual reference search was con-
ducted to identify previously undetected articles.
Inclusion criteria were original PK studies with docu-
mented number of blood samples in children up to the
age of 18 years. We excluded review articles, editorials,
conference abstracts and studies in adults aged 18 years
and over. Studies where data for blood samples were not
presented were also excluded. Data such as number of
patients, age group, mean weight, number of blood
samples, volume of blood per sample, total volume of
blood, name of drug and year of study were extracted.
One investigator performed the literature search and
data extraction (MIA). All studies conducted between
1967 and 2015 were identiﬁed and comparison made
between the four decades. Paediatric patients were
grouped as (1) neonates (<28 days); (2) infants (28 days
to under 2 years); (3) children (2–11 years); (4) adoles-
cents (12 to under 18 years).13
Statistical analysis
The samples and volume for each decade under consid-
eration were not normally distributed for some age
groups. Therefore, the number of samples and volume
for each decade were compared, using the Kruskal-Wallis
test. The mean ranks of each column were subsequently
compared using Dunn’s post hoc tests. p Values <0.05
were considered statistically signiﬁcant.
RESULTS
A total of 549 paediatric PK studies, which stated the
numbers of blood samples collected, were identiﬁed
between 1976 and 2015 (ﬁgure 1). A total of 177 studies
did not state the number of blood samples collected
(2 between 1976 and 1985, 55 between 1986 and 1995,
66 between 1996 and 2005, 54 between 2006 and 2015);
these studies were excluded. There were 52 studies
between 1976 and 1985, 105 between 1986 and 1995, 201
between 1996 and 2005 and 191 between 2006 and 2015
(table 1).
In total, 53 of the studies were neonatal studies, 46
involved infants, 282 involved children and 19 were ado-
lescent studies. The per cent of studies that used an
indwelling catheter ranged between 31% and 38% in
each decade. Other sampling methods included arterial
sampling (1%), heel prick (1%) and ﬁnger prick (2%).
In 50% of studies, the method was not stated. A total of
194 studies involved paediatric patients across the whole
age spectrum.
The total number of paediatric patients in PK studies
has increased over each decade from 748 in the earliest
decade to 9883 in the latest decade (table 1). TheFigure 1 Flow chart of the search performed.
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number of neonates increased each decade up to 2005.
The number in the last decade however fell sharply.
Most studies were conducted in the USA (218),
France (41) and the UK (39). There were 59 multi-
national studies.
The number of blood samples collected per paediatric
patient was signiﬁcantly higher in 1986–1995 than in any
other decade (p<0.001; table 2).
The number of samples collected per participant
increased between the ﬁrst two decades (p=0.013).
There was a decrease in the number of samples per par-
ticipant over the subsequent two decades (p=0.044 and
p<0.001, respectively). The number of blood samples
collected per child increased between the ﬁrst two
decades (p<0.039). Thereafter, it decreased again. The
number of blood samples collected per neonate
decreased between the second and third decades
(p=0.044).
There were no signiﬁcant differences in volume col-
lected per sample in any of the age groups (table 3).
Considering all age groups, the median volume per
sample ranged from 1 mL in the ﬁrst decade to 2 mL in
the second and third decades. Between 0.2 and 0.5 mL
was collected from neonates over four decades, with no
signiﬁcant differences observed between decades.
There was signiﬁcant variation in the total amount of
blood collected from each paediatric patient between
studies, ranging from 1 to 50 mL in the ﬁrst decade to
0.6 to 77 mL in the last decade (table 4).
The median total volume collected increased from 8
to 14 mL over the ﬁrst two decades. It subsequently fell
over the next two decades to 10 mL. These differences
however were not statistically signiﬁcant due to the large
interindividual variation. When all decades were com-
pared using Kruskal-Wallis test, total volume was statistic-
ally signiﬁcant for children and adolescents (table 4).
However, when the decades were individually compared
using Dunn’s multiple comparison test, the p values
were borderline for children and adolescents in the
second and fourth decades (p=0.055 for children and
p=0.045 for adolescents).
Fifty-six of the studies used the method of population
PK. There was a signiﬁcant difference in the frequency
of blood sampling between population PK studies
(median 5, IQR (3–7)) and non-population PK studies
(median 8, IQR (6–10); p=<0.001).
Twenty-nine studies collected more than 12 samples.
The number of these studies per decade ranged from
ﬁve in 1976–1985 to nine in 1985–1995 and 2006–2015.
The largest number of blood samples collected in chil-
dren was 27, and this study was performed in Canada in
1995 studying alfentanil.14
One study in 2007, of children aged 6–12 years, involved
the collection of 77 mL of blood during the course of
PK study of methylphenidate. In this Canadian study,
7 mL was taken 11 times over 24 hours.15 According to
the EMA guideline, these volumes exceeded the
maximum allowable total draw in lighter weighing chil-
dren (ie, those 20–23 kg), which is 42 mL assuming a
blood volume of 70 mL/kg. Similarly, another study in
2006, involving children aged 4–19 years, collected 5 mL
of blood 13 times over 24 hours (total 65 mL).16 Although
Table 1 Pharmacokinetic studies in the four decades
Age group
Number of studies (number of cannula studies) Number of patients
1976–1985 1986–1995 1996–2005 2006–2015 1976–1985 1986–1995 1996–2005 2006–2015
Neonates 9 (1) 18 (3) 18 (4) 8 (4) 188 385 423 231
Infants 12 (3) 6 (2) 17 (6) 11 (3) 250 162 376 467
Children 20 (13) 61 (20) 102 (36) 99 (32) 301 1011 2826 5466
Adolescents 1 (1) 4 (2) 3 (1) 11 (4) 9 36 107 328
Mixed age 10 (2) 16 (6) 61 (17) 62 (22) 297 376 2468 3391
Total 52 (20) 105 (33) 201 (64) 191 (68) 748 1970 6200 9883
Table 2 Blood samples per paediatric patient
Age group
Number of blood samples
Statistical analysis
(overall p value)
1976–1985
Median [IQR]
(range)
1986–1995
Median [IQR]
(range)
1996–2005
Median [IQR]
(range)
2006–2015
Median [IQR]
(range)
Neonates 6 [5–7] (1–8) 7 [6–9]* (1–14) 4 [3–7]* (1–11) 5 [3–7] (2–14) 0.047
Infants 6.5 [5–7] (2–9) 9 [6–11] (4–27) 8 [5–12] (3–12) 6 [4–8] (4–10) 0.261
Children 7 [5–9]Î (4–20) 9 [8–12]Î† (4–18) 8 [7–10] (2–19) 7 [5–9]† (2–20) <0.001
Adolescents 5 8 [7–9] (7–9) 9 [8–10] (8–10) 6 [4–9] (2–11) 0.300
Mixed age 8 [5–12] (5–18) 9 [6–12] (2–15) 8 [6–10] (1–16) 7 [6–9] (2–15) 0.229
Total 7 [5–8]‡ (1–20) 9 [6–11]‡xƒ (1–27) 8 [6–10]x (1–19) 7 [5–9]ƒ (2–20) <0.001
Only these pairs were significant: *(p=0.043), Î(p=0.039), †(p=<0.001), ‡(p=0.013), x(p=0.044) and ƒ(p=<0.001).
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the weights were not given in this study, an average child
aged 4 years will weigh ∼16 kg, so representing about 5%
of their TBV in 24 hours and exceeding the EMA guid-
ance of 3% of TBV.17
DISCUSSION
This study evaluated the number and volume of blood
collected per paediatric patient in PK studies over four
decades. The median number of blood samples col-
lected per paediatric patient varied between seven and
nine across all decades. More blood samples were col-
lected per paediatric patient in the second decade than
any other decade. Comparing the ﬁrst and last decades,
there has surprisingly been no overall change in the
number of blood samples collected in paediatric
patients. This trend was observed across all age groups
except in neonates. Neonates generally had fewer blood
samples than any other age group. The population PK
studies were associated with fewer blood samples.
Greater use of population PK may result in fewer blood
samples being collected.
There are currently no guidelines on the frequency of
blood sampling in children; hence, a highly varied
number of samples are used in paediatric PK studies as
shown in this review. The utility of guidelines however
depends on the type of PK study. For population PK
studies, it has been suggested that no more than six
samples need to be collected18 and for neonates, three
samples are thought to be optimal for the estimation of
PK parameters.19 In this review, the median frequency of
blood sampling in neonates was between ﬁve and seven.
Despite the recommendations for less frequent blood
sampling, Reed showed that the greater the number of
blood samples taken, the better the estimation of PK
parameters.20 This conclusion was reached after compar-
ing PK parameters obtained from 5 to 12 sampling time
points.20 This therefore needs to be balanced against
the need to limit the number of samples depending on
the patient age and disease.
The available guidelines on the volume of blood
samples for PK studies in children are highly varied with
most recommendations suggesting a range between 1%
and 5% of TBV within 24 hours and not more than 10%
of TBV within 8 weeks.21 Children’s TBV can be esti-
mated from their weight (70 mL/kg), and preterm neo-
nates have ∼90 mL/kg and term neonates 80 mL/kg.
This suggests that a 3 kg neonate will have a TBV of
about 240 mL. We found the largest TBV drawn from
preterm neonates to be 4 mL, in a PK study of cefopera-
zone.22 The weights of neonates in this study were not
reported; hence, it could not be exactly determined
whether the maximum allowable TBV draw based on
EMA recommendations was exceeded, but it would have
represented ∼1.5% of the TBV of a 3 kg term baby.10 In
another study of midazolam in term neonates, a sample
volume of 0.5 mL was taken on 14 occasions, total
volume 7 mL in 24 hours.23 Therefore, each individual
sample and total volume did not exceed 1% and 3%,
respectively, per EMA guideline for a 3 kg baby.
Table 3 Blood volume of each sample taken per paediatric patient
Age group
Volume of blood samples (mL)
1976–1985
Median [IQR] (range)
1986–1995
Median [IQR]
(range)
1996–2005
Median [IQR]
(range)
2006–2015
Median [IQR]
(range)
Statistical
analysis
(overall p value)
Neonates 0.3 [0.2–0.5] (0.2–0.5) 0.2 [0.2–0.8] (0.2–1) 0.5 [0.2–1] (0.1–2) 0.3 [0.2–0.6] (0.2–1) 0.754
Infants 0.5 1 [0.4–2] (0.4–2) 2 [1–2] (0.2–5) 2 [0.8–2] (0.1–2.5) 0.577
Children 4 [1–9] (0.5–10) 2 [1.5–3] (0.2–10) 2 [1–3] (0.1–10) 2 [1–3] (0.2–7) 0.599
Adolescents 7 8 [7–9] (7–9) 1 [0.7–2] (0.7–2) 2 [1–3] (1–3) 0.594
Mixed age 2 [1–3] (1–3) 1.5 [1–3] (0.5–3) 2 [1–3] (0.1–7) 1 [0.6–2] (0.1–5) 0.594
Total 1 [0.5–5] (0.2–10) 2 [1–3] (0.2–10) 2 [1–3] (0.1–10) 1.5 [1–2] (0.1–7) 0.226
Table 4 Total blood volume for all samples per paediatric patient
Age group
Total volume of blood samples (mL)
1976–1985
Median [IQR]
(range)
1986–1995
Median [IQR]
(range)
1996–2005
Median [IQR]
(range)
2006–2015
Median [IQR]
(range)
Statistical
analysis
(overall p value)
Neonates 2 [1.5–5] (1–5) 4 [2–8] (2–14) 2 [1–4] (0.6–7) 2 [0.9–4] (0.6–7) 0.241
Infants 3 6 [3–22] (3–41) 14 [5–30] (1–60) 10 [5–16] (0.6–16) 0.546
Children 20 [14–40] (9–50) 23 [10–30] (2–55) 18 [8–22] (1–60) 14 [6–20] (2–77) 0.041
Adolescents 35 32 [21–35] (21–35) 16 [7–18] (7–18) 8 [8–11] (8–11) 0.042
Mixed age 15 [7–27] (7–27) 13 [11–24] (5–24) 12 [5–16] (3–24) 10 [5–17] (0.6–50) 0.284
Total 8 [3–22] (1–50) 14 [6–25] (2–55) 12 [5–21] (0.6–60) 10 [5–18] (0.6–77) 0.213
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The maximum recommended allowable blood draw is
a percentage of blood volume per body weight. It is
often difﬁcult to ascertain whether the studies involv-
ing children and adolescents exceeded these recom-
mendations as they may have wide age ranges and only
quote a mean or median weight. Two Canadian studies
involved the collection of 77 and 65 mL, respectively,
over a 24-hour period in children.15 16 The maximum
recommended volumes were exceeded in the lightest
children recruited in one of these studies.15 The second
study of temozolomide, however, did not specify the
patient’s weight. It is therefore very important to look
at the whole age and weight ranges of children taking
part in PK studies when deciding the blood volumes
to be collected. Protocols may need to have different
regimens for different ages/weights if the population
studied is wide.
Blood samples were collected mainly from a catheter
or venous sampling. Catheter sampling is the most
convenient sampling method when repeated blood
collection is required and minimises the distress of
repeated blood sampling. However, a catheter requires
nursing care and monitoring; also, it may not always
last for the whole duration of the study.24 25 The other
sampling method identiﬁed was arterial sampling.
Unlike venous sampling, it requires greater expertise
and may result in bleeding. Venous sampling is also
generally preferred to heel pricks in neonates,
because it is less painful and more likely to provide
the required volume.26
The dangers of excessive blood sampling include the
increased risk of infection, bruising, pain and higher
rates of blood transfusion.27 A correlation between the
blood volume sampled and transfusion rate has already
been shown in neonates.28 A major limitation of this
study is that some studies did not report the results for
different paediatric age groups. Additionally, some
studies were also limited by the lack of data on weight.
Therefore, compliance of these studies with guidelines
could not be determined. Furthermore, an accurate
comparison within paediatric age groups is difﬁcult
because of the wide age range in paediatrics. Also, some
studies did not provide information on volume. Finally,
only one investigator carried out the literature search
and data extraction.
In conclusion, deﬁnitive evidence-based guidelines
should be developed regarding the maximum volume
and number of samples that should be collected in chil-
dren of various ages. There is presently no guideline on
frequency of blood sampling, and the guidelines on
volume are variable. More attention needs to be given to
reducing the number of blood samples and the total
volume of blood collected in an individual patient by
using microanalytical techniques and population PK
methods. Consideration should be given by researchers
to all ages/weights of potential children within the
study, as to whether the single volume or total volume of
blood exceeds current guidance.
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